MASSDEVICE ON CALL — Dr. George Bakris, the co-principal investigator for Medtronic‘s (NYSE:MDT) failed Symplicty-3 renal denervation trial, believes further clinical work should be tabled until a few key questions about the therapy are answered.
I just returned from the American College of Cardiology and wanted to write down a few of my 50,000-foot impressions from the meeting for, as the song goes, the times, they are a-changin’.
UPDATED March 31, 2014, with comment from Medtronic
Welcome to the latest edition of the MassDevice.com’s D+Vice Talk, our new webcast, in which we review medical device stories from the last week.
In this episode we start with updates from Capitol Hill, review highlights from the American College of Cardiology conference, consider the mixed FDA reports for Abbott’s MitraClip heart implant and debate Dr. Robert Hauser’s controversial proposal to overhaul the FDA.
Find all of today’s referenced stories here:
Sometimes the major annual medical meetings are jam-packed with significant and market-moving data. And then sometimes they’re like this year’s American College of Cardiology conference, with relatively limited useful data from an investing perspective.